Clinical Trial for Newly Diagnosed Myeloma Patients and More


IMWG Conference Series: Making Sense of Treatment Webinar Coming Soon Join us Thursday, December 14, 2023, at 11:00 a.m. PST/ 2:00 p.m. EST for the IMWG Conference Series, “Making Sense of Treatment.” Leading myeloma experts will discuss the latest myeloma research news from the 2023 American Society of Hematology (ASH) Annual Meeting and Expo. IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie will moderate the discussion, with Drs. María V. Mateos (University of Salamanca—Salamanca, Spain) and Thomas Martin (University of California San Francisco—San Francisco, CA) serving as panelists.


The Mayo Clinic’s PragMMatic Study Now Accruing Newly Diagnosed Multiple Myeloma Patients A new clinical trial administered by the Mayo Clinic, the PragMMatic Study, is now accruing newly diagnosed multiple myeloma (NDMM) patients. Led by the IMF’s International Myeloma Working Group (IMWG) members Drs. S. Vincent Rajkumar and Shaji Kumar, the study is for the first time comparing the efficacy and side effect profiles of the three most common treatment regimens for NDMM patients. This study is currently open to those recently diagnosed with multiple myeloma who are receiving treatment for this condition. Read the full article to learn more.


IMF Support Group Leaders Report Live During the 65th American Society of Hematology Annual Meeting and Exposition Tune in as the IMF brings myeloma support group leaders and patients to the 65th annual meeting of the American Society of Hematology (ASH), “the world’s most comprehensive hematology event of the year.” Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#ASH23 and #IMFASH23), Facebook, blogs, and videos. The IMF thanks these leaders for their care and commitment in sharing their experiences with the global myeloma community. We encourage you to visit the website and follow these leaders for their unique perspectives.


Join IMF Chief Medical Officer Dr. Joseph Mikhael and the ASH Support Group Leaders Team LIVE at ASH 2023 IMF Chief Medical Officer Dr. Joseph Mikhael along with the ASH Support Group Leader team go live to discuss key myeloma research takeaways from the 2023 American Society of Hematology meeting and exposition. This Facebook Live Event takes place on Monday, December 11, at 7:00 p.m. PST / 10:00 p.m. EST. Click the button below to visit the Facebook event page. Then click ‘Going’ to register.


GSK Announces Positive Results in a Phase I Trial of Blenrep On November 27, 2023, GSK announced positive results from the DREAMM-7 phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The trial demonstrated a significant improvement in progression-free survival (PFS) when belantamab mafodotin was combined with bortezomib and dexamethasone (BorDex) compared to the standard of care, daratumumab plus BorDex. Additionally, there was a strong trend towards improved overall survival (OS). The trial will continue to monitor OS outcomes. The safety and tolerability of the belantamab mafodotin regimen were consistent with the known profiles of the individual agents. Read the full press release to learn more.


Around the Web: Myeloma News To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. For this week, we encourage you to visit this article In Nature and learn about two studies that “investigate the genetic and epigenetic resistance mechanisms that lead to relapse in patients receiving T cell-engaging therapies targeting B cell maturation antigen (BCMA) and GPRC5D.” This study published in Blood Advances looks at “racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T-cell therapy.” This press release issued by Bristol Myers Squibb and 2seventy bio announces that “the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will meet to review data supporting the supplemental Biologics License Application (sBLA) for Abecma (idecabtagene vicleucel) for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on results from the pivotal Phase 3 KarMMa-3 study.” As always, we invite you to visit the IMF Newsroom for the most recent announcements in myeloma news.


Medicare Open Enrollment Period Ends on December 7th Medicare's Open Enrollment Period is October 15 - December 7. This timeframe is your chance to explore Medicare Plans and see what works for you. Plans can change from year to year, and your health needs may change, too. The International Myeloma Foundation and our InfoLine team do not have recommendations about Medicare. We do, however, encourage you to explore Medicare.gov, or contact your local State Health Insurance Assistance Program (SHIP) to get the phone number for Medicare assistance for your state.


#ASKDRDURIE \| Dr. Durie's Weekly Web Video Series How is the Black Swan Research Initiative Approaching Early Myeloma Development?

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

KTX-1001 (phase I trial – Now Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Fully Accrued)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Webinar Replays

Watch the Replay
IMF Patient and Family Webinar

Watch the Replay
M-Power Tampa

Watch the Replay
IMF Virtual Regional Community Workshop

See also, all of our events.

We Thank Our Sponsors:

AbbVie, Bristol Myers Squibb, GSK, Janssen Oncology, Karyopharm Therapeutics,
Pfizer, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.

We also thank individuals like you for your continued support!

Join the conversation at The International Myeloma Foundation

Facebook: /Myeloma | Twitter @IMFMyeloma | Instagram @IMFmyeloma

www.myeloma.org

This email was sent to by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873

We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Manage Subscriptions • Privacy Policy

View as web page